The position of aliskiren on cardiovascular disease in the light of the ALTITUDE study.

Abstract

Aliskiren is the only available orally active renin inhibitor blocking its catalytic activity. Based on prematurely terminated ALTITUDE study in high-risk patients with 2 diabetes type, who were treated with ACE inhibitors or AT1-blockers, The European Medicines Agency recommends not to use aliskiren in patients with diabetes or patients with moderate to severe renal impairment who are currently treated with ACE inhibitors or AT1-blockers.